381 related articles for article (PubMed ID: 29596304)
1. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.
Xiao XH; Lv LC; Duan J; Wu YM; He SJ; Hu ZZ; Xiong LX
Molecules; 2018 Mar; 23(4):. PubMed ID: 29596304
[TBL] [Abstract][Full Text] [Related]
2. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
3. Cdc42: Role in Cancer Management.
Qadir MI; Parveen A; Ali M
Chem Biol Drug Des; 2015 Oct; 86(4):432-9. PubMed ID: 25777055
[TBL] [Abstract][Full Text] [Related]
4. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer.
Cheng Z; Liu F; Wang G; Li Y; Zhang H; Li F
Cell Signal; 2014 Dec; 26(12):2667-73. PubMed ID: 25152372
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines.
Chen QY; Jiao DM; Yao QH; Yan J; Song J; Chen FY; Lu GH; Zhou JY
Int J Oncol; 2012 May; 40(5):1561-8. PubMed ID: 22266952
[TBL] [Abstract][Full Text] [Related]
6. miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42.
Li Y; Zhu X; Xu W; Wang D; Yan J
Biochem Biophys Res Commun; 2013 Feb; 431(3):560-5. PubMed ID: 23337504
[TBL] [Abstract][Full Text] [Related]
7. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.
Zuo Y; Wu Y; Chakraborty C
J Cell Physiol; 2012 Apr; 227(4):1399-407. PubMed ID: 21618528
[TBL] [Abstract][Full Text] [Related]
8. Targeting Rac and Cdc42 GTPases in Cancer.
Maldonado MDM; Dharmawardhane S
Cancer Res; 2018 Jun; 78(12):3101-3111. PubMed ID: 29858187
[TBL] [Abstract][Full Text] [Related]
9. Molecular subversion of Cdc42 signalling in cancer.
Murphy NP; Binti Ahmad Mokhtar AM; Mott HR; Owen D
Biochem Soc Trans; 2021 Jun; 49(3):1425-1442. PubMed ID: 34196668
[TBL] [Abstract][Full Text] [Related]
10. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42.
Fidyk N; Wang JB; Cerione RA
Biochemistry; 2006 Jun; 45(25):7750-62. PubMed ID: 16784226
[TBL] [Abstract][Full Text] [Related]
11. Role of Rho GTPases in breast cancer.
Tang Y; Olufemi L; Wang MT; Nie D
Front Biosci; 2008 Jan; 13():759-76. PubMed ID: 17981586
[TBL] [Abstract][Full Text] [Related]
12. DNA damage response regulation by microRNAs as a therapeutic target in cancer.
Majidinia M; Yousefi B
DNA Repair (Amst); 2016 Nov; 47():1-11. PubMed ID: 27697364
[TBL] [Abstract][Full Text] [Related]
13. Progress in the therapeutic inhibition of Cdc42 signalling.
Murphy NP; Mott HR; Owen D
Biochem Soc Trans; 2021 Jun; 49(3):1443-1456. PubMed ID: 34100887
[TBL] [Abstract][Full Text] [Related]
14. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy.
Humphries B; Yang C
Oncotarget; 2015 Mar; 6(9):6472-98. PubMed ID: 25762624
[TBL] [Abstract][Full Text] [Related]
15. Cdc42 in oncogenic transformation, invasion, and tumorigenesis.
Stengel K; Zheng Y
Cell Signal; 2011 Sep; 23(9):1415-23. PubMed ID: 21515363
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cdc42 in cancer.
Arias-Romero LE; Chernoff J
Expert Opin Ther Targets; 2013 Nov; 17(11):1263-73. PubMed ID: 23957315
[TBL] [Abstract][Full Text] [Related]
17. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells.
Liu M; Lang N; Qiu M; Xu F; Li Q; Tang Q; Chen J; Chen X; Zhang S; Liu Z; Zhou J; Zhu Y; Deng Y; Zheng Y; Bi F
Int J Cancer; 2011 Mar; 128(6):1269-79. PubMed ID: 20473940
[TBL] [Abstract][Full Text] [Related]
18. Structure and role of WASP and WAVE in Rho GTPase signalling in cancer.
Lane J; Martin T; Weeks HP; Jiang WG
Cancer Genomics Proteomics; 2014; 11(3):155-65. PubMed ID: 24969695
[TBL] [Abstract][Full Text] [Related]
19. Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers.
Su M; Xiao Y; Ma J; Tang Y; Tian B; Zhang Y; Li X; Wu Z; Yang D; Zhou Y; Wang H; Liao Q; Wang W
Mol Cancer; 2019 Apr; 18(1):90. PubMed ID: 30999909
[TBL] [Abstract][Full Text] [Related]
20. MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.
Wang YX; Chen YR; Liu SS; Ye YP; Jiao HL; Wang SY; Xiao ZY; Wei WT; Qiu JF; Liang L; Liao WT; Ding YQ
Oncotarget; 2016 Dec; 7(51):84826-84838. PubMed ID: 27769041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
